Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Ju Fu Tang Biotech Holdings Co., Ltd
菊福堂生物控股有限公司

(formerly known as "WMHW Holdings Limited 萬民好物控股有限公司")
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 8217)

PROFIT WARNING

This announcement is made by Ju Fu Tang Biotech Holdings Co., Ltd (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**") and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the Company that, based on a preliminary review of the information currently available to the Board, including the latest unaudited interim consolidated management accounts of the Group for the six months ended 30 September 2026 (the "**Period**") that the Group is expected to record net loss attributable to owners of the Company of approximately HK$13.1 million, compared to net profit of approximately HK$21.4 million for the six months ended 30 September 2025. The net loss is mainly due to (i) the net fair value loss on financial assets at fair value through profit or loss of approximately HK$9.3 million for the Period, as compared with a gain of approximately HK$23.7 million for the corresponding period in 2025; and (ii) the increase in administrative and other operating expenses by approximately HK$1.3 million as the Group expanded its construction business and developed its health technology business.

The information contained in this announcement is only based on the preliminary assessment by the Company's management which is based on the latest financial information of the Group available to the management. The above information may be subject to further adjustments based on further updated information, and following the review of the Company's audit committee of the Board. Shareholders and potential investors of the Company are advised to refer to the results announcement of the Company for the Period, which will be published by the Company on 30 November 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ju Fu Tang Biotech Holdings Co., Ltd
Chen Jian
Executive Director

Hong Kong, 27 November 2026

As at the date of this announcement, the executive Directors are Mr. Chen Jian and Ms. Yu Xiao and the independent non-executive Directors are Mr. Wong Chi Kan, Ms. Wong Mei Yin Mian and Ms. Lao In Iam.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at http://www.hklcnews.com/8217.